COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,884 Articles (22,568 medRxiv, 8,316 bioRxiv)

Most recent first Previous |  Page 1067: Articles 10661-10670  | Next

Peptide-antibody Fusions Engineered by Phage Display Exhibit Ultrapotent and Broad Neutralization of SARS-CoV-2 Variants
Labriola, J. M., Miersch, S., Chen, G., Chen, C., Pavlenco, A., Pisanu, F., Caccuri, F., Zani, A., Sharma, N., Feng, A., Leung, D. W., Caruso, A., Amarasinghe, G. K., Sidhu, S.
10.1101/2021.11.29.470362 — Posted: 2021-11-30
In silico study on the effects of disulfide bonds in ORF8 of SARS-CoV-2
Cheng, Y., Peng, X.
10.1101/2021.11.29.470346 — Posted: 2021-11-30
Protective immunity of the primary SARS-CoV-2 infection reduces disease severity post re-infection with Delta variants in Syrian hamsters
Mohandas, S., Yadav, P., Shete, A., Nyayanit, D., Jain, R., Sapkal, G. N., Mote, C.
10.1101/2021.11.28.470293 — Posted: 2021-11-30
A large-scale systematic survey of SARS-CoV-2 antibodies reveals recurring molecular features
Wang, Y., Yuan, M., Peng, J., Wilson, I. A., Wu, N. C.
10.1101/2021.11.26.470157 — Posted: 2021-11-30
sgDI-tector: defective interfering viral genome bioinformatics for detection of coronavirus subgenomic RNAs
Di Gioacchino, A., Legendre, R., Rahou, Y., Najburg, V., Charneau, P., Greenbaum, B. D., Tangy, F., van der Werf, S., Cocco, S., Komarova, A. V.
10.1101/2021.11.30.470527 — Posted: 2021-11-30
Main protease mutants of SARS-CoV-2 variants remain susceptible to PF-07321332
Ullrich, S., Ekanayake, K. B., Otting, G., Nitsche, C.
10.1101/2021.11.28.470226 — Posted: 2021-11-30
Case Study of High-Throughput Drug Screening and Remote Data Collection for SARS-CoV-2 Main Protease by Using Serial Femtosecond X-ray Crystallography
Guven, O., Gul, M., Ayan, E., Johnson, J. A., Cakilkaya, B., Usta, G., Ertem, F. B., Tokay, N., Yuksel, B., Gocenler, O., Buyukdag, C., Botha, S., Ketawala, G., Su, Z., Hayes, B., Poitevin, F., Batyuk, A., Yoon, C. H., Kupitz, C., Durdagi, S., Sierra, R. G., DeMirci, H.
10.1101/2021.11.28.468932 — Posted: 2021-11-30
Differential neutralization and inhibition of SARS-CoV-2 variants by antibodies elicited by COVID-19 mRNA vaccines
Wang, L., Kainulainen, M. H., Jiang, N., Di, H., Bonenfant, G., Mills, L., Currier, M., Shrivastava-Ranjan, P., Calderon, B. M., Sheth, M., Mann, B. R., Hossain, J., Lin, X., Lester, S., Pusch, E., Jones, J., Cui, D., Chatterjee, P., Jenks, H. M., Morantz, E., Larson, G., Hatta, M., Harcourt, J., Tamin, A., Lin, Y., Tao, Y., Zhao, K., Lacek, K., Burroughs, A., Wong, T., Tong, S., Barnes, J. R., Tenforde, M. W., Self, W. H., Shapiro, N. I., Exline, M. C., Files, D. C., Gibbs, K. W., Hager, D. N., Patel, M., Laufer Halpin, A. S., McMullan, L. K., Lee, J. S., Spiropoulou, C. F., Thornburg, N. J., Oberste, M. S., Dugan, V., SSEV Bioinformatics Working Group, , Wentworth, D. E., Zhou, B.
10.1101/2021.11.24.469906 — Posted: 2021-11-30
Myeloid cell-driven nonregenerative pulmonary scarring is conserved in multiple nonhuman primate species regardless of SARS-CoV-2 infection modality
Fears, A. C., Beddingfield, B. J., Chirichella, N. R., Slisarenko, N., Killeen, S. Z., Redmann, R. K., Goff, K., Spencer, S., Picou, B., Golden, N., Bush, D. J., Branco, L. M., Boisen, M. L., Gao, H., Montefiori, D., Blair, R. V., Doyle-Meyers, L. A., Russel-Lodrigue, K. E., Maness, N. J., Roy, C. J.
10.1101/2021.11.28.470250 — Posted: 2021-11-30
A recombinant SARS-CoV-2 RBD antigen expressed in insect cells elicits immunogenicity and confirms safety in animal models
Choque-Guevara, R., Poma-Acevedo, A., Montesinos-Millan, R., Rios-Matos, D., Gutierrez-Manchay, K., Montalvan, A., Quinones-Garcia, S., Cauti-Mendoza, M. d. G., Agurto-Arteaga, A., Ramirez-Ortiz, I., Criollo-Orozco, M., Huaccachi-Gonzales, E., Lazaro, Y. K. R., Perez-Martinez, N., Isasi-Rivas, G., Sernaque-Aguilar, Y., Villanueva-Perez, D., Vallejos-Sanchez, K., Fernandez-Sanchez, M., Guevara, L., Fernandez-Diaz, M., Zimic, M., COVID-19 Working Group in Peru
10.1101/2021.11.26.470043 — Posted: 2021-11-30

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).